Solventum Corporation (SOLV) — ESG & Values Scores

Environment story

Solventum discloses minimal quantitative environmental data in provided documents. No Scope 1, 2, or 3 emissions figures disclosed. Net-zero target year not disclosed. Company emphasizes sustainability and ESG risk review per board governance, but lacks transparent GHG reporting, decarbonization infrastructure investment detail, and clear climate commitments. Tariff-related supply-chain cost increases suggest elevated operational supply-chain vulnerability. No material controversies identified in provided filings regarding toxic waste, water consumption, or habitat loss; however, absence of disclosure does not confirm mitigation.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Board Risk Review - Sustainability & ESG

Board conducts regular review of company's risk profile including sustainability matters as part of standard governance oversight.

Board-level accountability for ESG risks; no specific decarbonization programs or targets disclosed.
Supply Chain Separation & Relocation

Company investing in manufacturing relocation and supply-chain optimization to separate from 3M's supply agreements and reduce dependency; capital spending on manufacturing footprint optimization.

Long-term supply-chain resilience; no quantified environmental benefit or carbon reduction target disclosed.

Social story

Solventum reports 20,584 total employees as of 12/31/2025. Disclosed leadership includes 7 named executives, of whom 3 are women (Heather Knight, Tammy Gomez, Marcela Kirberger, Amy Landucci = 4 women out of 7 named = 57% representation in disclosed named executive officer group). Board composition shows 12 directors; visual board roster indicates representation of women and diversity, though precise percentages not stated in provided documents. CEO-to-median-worker pay ratio not explicitly disclosed; CEO Bryan Hanson's compensation structure shows 92% at-risk pay. No active union-suppression activities, major strikes, or labor litigation documented in provided filings. Supply-chain labor practices not detailed; no human-rights controversies disclosed. Separation from 3M created transition costs and staff reductions (20,584 employees in 2025 vs. 21,981 in 2024 and 22,007 in 2023), indicating ongoing workforce adjustment.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Named Executive Officer Diversity

4 women among 7 named executives disclosed (Heather Knight, Tammy Gomez, Marcela Kirberger, Amy Landucci); 3 men (Bryan Hanson CFO Wayde McMillan, Paul Harrington).

57% female representation in named executive officer cohort; board also includes female directors and leadership roles.
Compensation Alignment & Pay Structure

CEO total target pay mix is 92% at-risk (performance-based); average NEO target pay mix is 81% at-risk, aligned to annual incentive, performance shares, and RSUs based on financial metrics.

Pay structure incentivizes performance; does not directly address pay equity or median-worker ratio transparency.
Board Talent Committee Oversight

Board Talent Committee (chaired by Karen J. May) oversees compensation, talent development, and human capital management.

Governance structure for HR oversight; specific labor relations, union standing, or workplace safety metrics not disclosed in provided documents.

Governance story

Solventum Board comprises 12 directors; all independent except CEO Bryan Hanson, yielding approximately 92% board independence (11 of 12). No dual-class share structure disclosed; company operates with single-class common stock. Board governance includes independent Board Chair (Carrie S. Cox), majority-vote director election standard, annual Board self-assessment, and regular executive sessions without management. Directors subject to age retirement at 75; other board service limited to four public companies. Audit Committee has designated financial expert. Lobbying expenditures and PAC contributions not quantified in provided filings. No active antitrust proceedings, significant regulatory fines, or SEC consent decrees disclosed in provided documents. CEO compensation clawback policy and anti-pledging/anti-hedging policies in place. Company subject to extensive regulatory oversight (FDA, HIPAA, GDPR, CCPA, China PIPL) per 10-K risk factors; no material compliance violations or SEC enforcement actions disclosed in provided filings.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Independent Board Chair & Committee Structure

Carrie S. Cox serves as independent Board Chair; four Board committees (Audit, Governance, Talent, Science/Technology/Quality) chaired by independent directors.

Strong governance separation of Board Chair and CEO; committee independence ensures checks and balances.
Annual Board & Committee Self-Assessment

Board conducts annual self-evaluation and assessment of committee effectiveness; periodic director education.

Continuous governance improvement and accountability; enhances Board effectiveness.
Majority-Vote Standard for Director Elections

Directors elected by majority of votes cast (not plurality); candidates receiving majority support are elected; transition to annual director elections beginning in 2028.

Enhanced shareholder accountability; directors standing for election annually by 2028 (staggered three-class structure transitioned to annual).
Anti-Pledging, Anti-Hedging, Anti-Short Selling Policy

Section 16 officers and directors prohibited from pledging shares, hedging, or short-selling Solventum stock.

Alignment of executive and director interests with shareholder value; reduces conflicts of interest.
Code of Conduct & Compliance Program

All employees required to follow Code of Conduct; Chief Compliance Officer reports to Audit Committee; ethics hotline for reporting concerns; no retaliation policy.

Embedded ethical framework and accountability; direct Audit Committee oversight of compliance.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Solventum Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Solventum Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)